Latest Insider Transactions at Uro Gen Pharma Ltd. (URGN)
This section provides a real-time view of insider transactions for Uro Gen Pharma Ltd. (URGN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of UroGen Pharma Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of UroGen Pharma Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 09
2024
|
Dong Kim Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+6.21%
|
-
|
|
Sep 09
2024
|
Jason Drew Smith General Counsel |
SELL
Open market or private sale
|
Direct |
1,521
-5.69%
|
$19,773
$13.08 P/Share
|
|
Sep 09
2024
|
Jason Drew Smith General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
3,333
+11.08%
|
-
|
|
Sep 09
2024
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
859
-0.59%
|
$11,167
$13.08 P/Share
|
|
Sep 09
2024
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,666
+1.13%
|
-
|
|
Jun 10
2024
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,153
-3.45%
|
$66,989
$13.08 P/Share
|
|
Jun 10
2024
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.27%
|
-
|
|
Mar 18
2024
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,000
-7.92%
|
$168,000
$14.05 P/Share
|
|
Jan 31
2024
|
Jason Drew Smith General Counsel |
SELL
Open market or private sale
|
Direct |
4,993
-6.82%
|
$74,895
$15.74 P/Share
|
|
Jan 31
2024
|
Jason Drew Smith General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.53%
|
-
|
|
Jan 31
2024
|
Dong Kim Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,333
+11.14%
|
-
|
|
Jan 31
2024
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,789
-0.83%
|
$56,835
$15.74 P/Share
|
|
Jan 31
2024
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,666
+1.44%
|
-
|
|
Aug 31
2023
|
Jason Drew Smith General Counsel |
SELL
Open market or private sale
|
Direct |
3,800
-17.11%
|
$68,400
$18.01 P/Share
|
|
Aug 31
2023
|
Jason Drew Smith General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
8,334
+27.29%
|
-
|
|
Jul 26
2023
|
Fred E Cohen Director |
BUY
Grant, award, or other acquisition
|
Indirect |
69,339
+50.0%
|
$624,051
$9.54 P/Share
|
|
Jan 31
2023
|
Elizabeth A. Barrett Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,333
+2.75%
|
-
|
|
Jan 31
2023
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,900
-0.43%
|
$19,000
$10.12 P/Share
|
|
Jan 31
2023
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,833
+0.85%
|
-
|
|
Jan 31
2023
|
Jason Drew Smith General Counsel |
SELL
Open market or private sale
|
Direct |
1,636
-5.63%
|
$16,360
$10.12 P/Share
|
|
Jan 31
2023
|
Jason Drew Smith General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
3,333
+10.11%
|
-
|
|
Jan 20
2023
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
122,677
+45.55%
|
$613,385
$5.0 P/Share
|
|
Oct 31
2022
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
258
-1.07%
|
$2,838
$11.85 P/Share
|
|
Oct 31
2022
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+2.02%
|
-
|
|
Oct 21
2022
|
Ran Nussbaum Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
47,999
+3.14%
|
$239,995
$5.94 P/Share
|
|
Sep 14
2022
|
Arie Belldegrun Director |
BUY
Exercise of conversion of derivative security
|
Direct |
160,000
+28.13%
|
$800,000
$5.0 P/Share
|
|
Aug 31
2022
|
Jason Drew Smith General Counsel |
SELL
Open market or private sale
|
Direct |
3,606
-22.85%
|
$25,242
$7.21 P/Share
|
|
Aug 31
2022
|
Jason Drew Smith General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
8,333
+34.56%
|
-
|
|
Aug 31
2022
|
Arie Belldegrun Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,241
+1.29%
|
$16,205
$5.0 P/Share
|
|
Aug 01
2022
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
259
-1.08%
|
$1,813
$7.81 P/Share
|
|
Jul 31
2022
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+2.04%
|
-
|
|
Jun 16
2022
|
Ran Nussbaum Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
2,211
+0.15%
|
$11,055
$5.0 P/Share
|
|
Jun 06
2022
|
Ran Nussbaum Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,030
+0.07%
|
$5,150
$5.0 P/Share
|
|
Apr 30
2022
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
254
-1.07%
|
$1,524
$6.62 P/Share
|
|
Apr 30
2022
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+2.06%
|
-
|
|
Jan 31
2022
|
Elizabeth A. Barrett Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,195
-1.32%
|
$57,365
$7.58 P/Share
|
|
Jan 31
2022
|
Elizabeth A. Barrett Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,333
+2.85%
|
-
|
|
Jan 31
2022
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,374
-2.87%
|
$9,618
$7.58 P/Share
|
|
Jan 31
2022
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+4.88%
|
-
|
|
Jan 31
2022
|
Molly Henderson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
331
-5.93%
|
$2,317
$7.58 P/Share
|
|
Jan 31
2022
|
Molly Henderson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
666
+10.66%
|
-
|
|
Jan 31
2022
|
Jason Drew Smith General Counsel |
SELL
Open market or private sale
|
Direct |
414
-5.27%
|
$2,898
$7.58 P/Share
|
|
Jan 31
2022
|
Jason Drew Smith General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
833
+9.58%
|
-
|
|
Jan 26
2022
|
Mark Schoenberg Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
111
-0.5%
|
$888
$8.09 P/Share
|
|
Jan 26
2022
|
Mark Schoenberg Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
209
+0.93%
|
-
|
|
Jan 04
2022
|
Elizabeth A. Barrett Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
46,968
-13.61%
|
$422,712
$9.15 P/Share
|
|
Jan 03
2022
|
Elizabeth A. Barrett Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
105,689
+23.44%
|
-
|
|
Nov 30
2021
|
Molly Henderson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,587
-34.49%
|
$31,044
$12.03 P/Share
|
|
Nov 30
2021
|
Molly Henderson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+40.0%
|
-
|
|
Nov 30
2021
|
Jason Drew Smith General Counsel |
SELL
Open market or private sale
|
Direct |
3,803
-35.11%
|
$45,636
$12.03 P/Share
|